Hiroshi Tanaka1, Satoshi Kanako, Shosaku Abe. 1. Third Department of Internal Medicine, Sapporo Medical University school of Medicine, Japan. tanakah@sapmed.ac.jp
Abstract
BACKGROUND: The pharmacologic actions of prostaglandin E(2) (PGE(2)) are mediated through specific E-prostanoid (EP)-1, EP-2, EP-3, and EP-4 receptors. In this study, we determined which PGE(2) receptor subtype(s) contribute to the prevention of allergen-induced bronchoconstriction. METHODS: We assessed the effects of these receptor agonists in ovalbumin (OA)-sensitized guinea pigs. The prostaglandin E receptor-subtype agonists tested were ONO-DI-004 (EP-1), ONO-AE1-259 (EP-2), ONO-AE-248 (EP-3), ONO-AE1-329 (EP-4), and sulprostone (EP-1 and EP-3) [Ono Pharmaceutical Company; Osaka, Japan]. We treated the animals with either PGE(2) or these agonists 15 min before OA challenge and measured respiratory resistance at 15 min, 1 h, and 3 h. RESULTS: Allergen-induced bronchoconstriction was significantly (p < 0.01) suppressed at doses > 85 nmol/kg of PGE(2). The respiratory resistance elevations 15 min after OA challenge were significantly (p < 0.01) suppressed by preadministration of EP-2 and EP-4 agonists, but airway responsiveness to inhaled methacholine did not improve. EP-1, EP-3, or EP-1/EP-3 agonists had no effect on any parameter. CONCLUSIONS: These results suggest that inhibition of OA-induced bronchoconstriction by PGE(2) acts through EP-2 and EP-4 receptors.
BACKGROUND: The pharmacologic actions of prostaglandin E(2) (PGE(2)) are mediated through specific E-prostanoid (EP)-1, EP-2, EP-3, and EP-4 receptors. In this study, we determined which PGE(2) receptor subtype(s) contribute to the prevention of allergen-induced bronchoconstriction. METHODS: We assessed the effects of these receptor agonists in ovalbumin (OA)-sensitized guinea pigs. The prostaglandin E receptor-subtype agonists tested were ONO-DI-004 (EP-1), ONO-AE1-259 (EP-2), ONO-AE-248 (EP-3), ONO-AE1-329 (EP-4), and sulprostone (EP-1 and EP-3) [Ono Pharmaceutical Company; Osaka, Japan]. We treated the animals with either PGE(2) or these agonists 15 min before OA challenge and measured respiratory resistance at 15 min, 1 h, and 3 h. RESULTS: Allergen-induced bronchoconstriction was significantly (p < 0.01) suppressed at doses > 85 nmol/kg of PGE(2). The respiratory resistance elevations 15 min after OA challenge were significantly (p < 0.01) suppressed by preadministration of EP-2 and EP-4 agonists, but airway responsiveness to inhaled methacholine did not improve. EP-1, EP-3, or EP-1/EP-3 agonists had no effect on any parameter. CONCLUSIONS: These results suggest that inhibition of OA-induced bronchoconstriction by PGE(2) acts through EP-2 and EP-4 receptors.
Authors: Zbigniew Zasłona; Katsuhide Okunishi; Emilie Bourdonnay; Racquel Domingo-Gonzalez; Bethany B Moore; Nicholas W Lukacs; David M Aronoff; Marc Peters-Golden Journal: J Allergy Clin Immunol Date: 2013-09-24 Impact factor: 10.793
Authors: James V Michael; Adelina Gavrila; Ajay P Nayak; Tonio Pera; Jennifer R Liberato; Steven R Polischak; Sushrut D Shah; Deepak A Deshpande; Raymond B Penn Journal: FASEB J Date: 2019-01-02 Impact factor: 5.191
Authors: Zbigniew Zasłona; Ewelina Flis; Mieszko M Wilk; Richard G Carroll; Eva M Palsson-McDermott; Mark M Hughes; Ciana Diskin; Kathy Banahan; Dylan G Ryan; Alexander Hooftman; Alicja Misiak; Jay Kearney; Gunter Lochnit; Wilhelm Bertrams; Timm Greulich; Bernd Schmeck; Oliver J McElvaney; Kingston H G Mills; Ed C Lavelle; Małgorzata Wygrecka; Emma M Creagh; Luke A J O'Neill Journal: Nat Commun Date: 2020-02-26 Impact factor: 14.919